Lonza collaborates with AbTis to extend Bioconjugation capabilities

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox

Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations

JB Pharma publishes its maiden sustainability report

Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%

AGC begins study to expand its Bio-CDMO capability in Japan

Cadila and CII launches joint national campaign for rabies-free India by 2030

Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone

Merck invests € 130 million + to strengthen manufacturing capabilities in France

Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025

Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'

India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency

FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations

Feeling younger can help us rehabilitate faster : Study

Researchers from Bar-Ilan University find that even in old age, feeling young can lower the risks of developing physical disability and morbidity

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.